These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 10494326)

  • 1. [New therapies in neurology, but who benefits?].
    Vermeulen M; de Haan RJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1764-6. PubMed ID: 10494326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivastigmine for Alzheimer's disease.
    Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
    Maloteaux JM
    Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA
    Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivastigmine (Exelon) for Alzheimer's disease.
    Med Lett Drugs Ther; 2000 Oct; 42(1089):93-4. PubMed ID: 11015159
    [No Abstract]   [Full Text] [Related]  

  • 8. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    Bullock R
    Int J Clin Pract; 2002 Apr; 56(3):206-14. PubMed ID: 12018828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
    Auriacombe S; Pere JJ;
    Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442
    [No Abstract]   [Full Text] [Related]  

  • 11. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
    Schölzel-Dorenbos CJ
    Ned Tijdschr Geneeskd; 2002 Mar; 146(10):494. PubMed ID: 11913117
    [No Abstract]   [Full Text] [Related]  

  • 12. Do the benefits of currently available treatments justify early diagnosis and treatment of amyotrophic lateral sclerosis? Arguments against.
    Ludolph AC; Riepe MW
    Neurology; 1999; 53(8 Suppl 5):S46-9; discussion S55-7. PubMed ID: 10560638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
    Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
    IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
    Doody RS
    J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-dopa in neurological disease: current status.
    Yahr MD
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():494-511. PubMed ID: 4561071
    [No Abstract]   [Full Text] [Related]  

  • 16. [Adverse efects of riluzole (Rilutek) in the treatment of amyotrophic lateral sclerosis].
    Roch-Torreilles I; Camu W; Hillaire-Buys D
    Therapie; 2000; 55(2):303-12. PubMed ID: 10967703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slowing down ALS--is this good or bad?
    Munsat TL
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2001 Mar; 2 Suppl 1():S19-22. PubMed ID: 11465919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The advance in the research and therapeutic trials of amyotrophic lateral sclerosis].
    Moriwaka F; Tashiro K
    Rinsho Shinkeigaku; 2000 Dec; 40(12):1258-60. PubMed ID: 11464472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.
    Bullock R; Passmore P; Wilkinson D; Howard R; Jones R
    BMJ; 2000 Feb; 320(7233):511-2. PubMed ID: 10678874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.